2000
DOI: 10.1002/1521-3773(20000804)39:15<2710::aid-anie2710>3.0.co;2-p
|View full text |Cite
|
Sign up to set email alerts
|

Small-Molecule Inhibitors of HIV-1 Protease Dimerization Derived from Cross-Linked Interfacial Peptides

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
34
0

Year Published

2001
2001
2007
2007

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 45 publications
(34 citation statements)
references
References 4 publications
0
34
0
Order By: Relevance
“…Additionally, inhibitors that interfere with BACE dimerization leading to an enrichment of monomers could result in a reduction of the activity of this rate-limiting enzyme for amyloid pathology, even if such BACE monomers were stable. Therapeutic disruption of dimers was already successfully shown for the human immunodeficiency virus 1 protease, which acts as a homodimer, each unit contributing one catalytic aspartate to the active site dyad (67,68).…”
Section: Discussionmentioning
confidence: 99%
“…Additionally, inhibitors that interfere with BACE dimerization leading to an enrichment of monomers could result in a reduction of the activity of this rate-limiting enzyme for amyloid pathology, even if such BACE monomers were stable. Therapeutic disruption of dimers was already successfully shown for the human immunodeficiency virus 1 protease, which acts as a homodimer, each unit contributing one catalytic aspartate to the active site dyad (67,68).…”
Section: Discussionmentioning
confidence: 99%
“…The main dimerisation region is folded as an interdigitating N-and Cterminal four stranded β-sheet. The group of Chmielewski using rational design developed inhibitors of the PR dimerisation derived from crosslinked interfacial peptides corresponding to this conserved β-sheet region and identified the minimal structure necessary for the activity of these peptides [107]. Moreover in an attempt to improve its activity a focused library on the basis of this minimized molecule was designed (compound 6) in which certain side chains were substituted by different natural and non natural amino acid side chains, see Fig (4).…”
Section: Hiv Protease Dimerisation Inhibitorsmentioning
confidence: 99%
“…In subsequent studies the inf luence of variations in both the peptide sequences and the linker were examined. Mutations in the peptide sequences led to a new inhibitor with a slightly higher IC 50 of 680 nM, but with a significantly lower molecular weight (933 g mol -1 compared with 1586 g mol -1 ) [64]. Interestingly, in this sequence a nonnatural amino acid with an appending cyclohexyl group was used.…”
Section: Dimerization Inhibitors Of Hiv-1 Proteasementioning
confidence: 99%